Welgus Howard G. 4
4 · Arcutis Biotherapeutics, Inc. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
Welgus Howard G.
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-09-02−10,000→ 0 totalExercise: $1.68Exp: 2029-03-13→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2025-09-02+10,000→ 110,206 total - Sale
Common Stock
2025-09-02$15.64/sh−10,000$156,383→ 100,206 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.45 to $15.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This option is fully vested.